No matching results for ''
Tip: Try a valid symbol or a specific company name for relevant results
Work & Management
UK markets closed
Urban appeal of city centre homes
Urban living is back in fashion after a brief move away from cities during the pandemic
Guardant Health, Inc. (GH)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 02:41PM EDT. Market open.
2,133 reactions on $GH conversation
Sign in to post a message.
Can’t believe this site just gave me a 43% winner. (
Massively undervalued. $3bn market cap with $1.6bn cash. Revenues of $460m-$470m expected this year. Clinical volumes up 47%. Shield LDT now launched.
This stock has suffered a sharp PPS decline to a level that it now looks to be a very good bargain basement play. It has great technology and an enormous TAM, and the EPIC deal is going to speed it's sales growth significantly, as it expands its product offerings. It is the clear leader in "liquid biopsy" and the many ways this technology can be used is quite promising for huge profits over time as sales growth is set to explode, IMO. Please don't listen to the short sellers that have latched onto this stock as it suffered a price decline in a difficult market environment. If you buy and hold till the market swings into a more positive mood, it will be recognized for the growth and profit potential that it has. Test results coming by the end of the year should help PPS from here. With its current $3 B MC and strong sales growth, it should be expected to provide a great investment for those that buy and patiently hold. GLTY and please do your own research and DD and never base your decisions on posters.
I am not understanding what Doctor would prescribe a test that is not FDA approved? Am I missing something?
Has the FDA approved this test? Has the test been accepted by any insurance networks?
Sell a big loss. Just hold onto it
Hope one day it may go up again
worse investment ever
On the other hand profitability for testing isn't easy :
Illumina (NASDAQ:ILMN) saw its Q1 2022 net income decline ~41% compared to the prior-year period due to a significant operating loss from its GRAIL division, which was acquired in August 2021.
EXAS tried marketing a non approved early version of a stool CRC screening test called PreGenPlus in 2007. FDA was not pleased and sent EXAS a letter saying they believed regulatory approval was required for their device. Market responded as you would expect and the stock was punished.
If the ECLIPSE test doesn’t produce outstanding results, this stock is DOA
Almost a 10% down day. Rock solid. Blame it on the he Nasdaq; everyone else does. Only off 66% from its high. Guess that is a Nasdaq thing too.
Strong move into earnings, only off 17% in a week. This life saver has it all, huh?
How can any corporation in 'health care' be unprofitable ?
Overpaid top management is one of the usual suspects.
It’s a long way reach that $123 target price. Can’t see that happening, regardless of valuation, underselling, overselling, or anything else.
should really by $20. this has been so overvalued,. Taken my lumps elsewhere though
Huge mistake from being swept up from the noble goal of predictive diagnostics, while ignoring the company's performance.
The question now is to hold and hope for a buyout, or sell into the bounce.
Unless the find a way to become profitable, the euphoria of last year is gone.
Best hope GH does not have an AMRN moment after their report. Clearly showing losses on the books tomorrow is not going to make the share price go up. A negatively received earnings report will send this below $45.
Down market due to margin calls, but great buying opportunity.
1 million pensioners risk missing out on Rishi Sunak’s one-off £650 payment
Yahoo Finance UK
‘Rough justice’: Sunak hands wealthy pensioners £850 while poor families lose out, analysis shows
Fusion reactors could provide much more power than previously thought, study suggests
© 2022 Yahoo. All rights reserved.
About our ads